Venture roundup: Cabaletta, Thousand Oaks, Sojournix

Autoimmune company Cabaletta Bio Inc. (Radnor, Pa.), CMC services play Thousand Oaks Biopharmaceuticals Inc. (Haimen, China) and women's health company Sojournix Inc. (Waltham, Mass.) each announced venture rounds of at least $44 million on Jan. 3.

Cabaletta intends to use its $50M series B funding to bring its lead product, DSG3-CAART, into the clinic to treat the skin-blistering autoimmune disease pemphigus vulgaris. The candidate comprises chimeric autoantigen receptor T cells (CAAR T cells) targeting Desmoglein 3 (DSG3)...